CUE RSI Strategy
Today’s Change (Nov 6, 2026)
—
A symphony is an automated trading strategy — Learn more about symphonies here
About
A simple rule-based strategy that buys volatile biotech stock CUE only after heavy recent selling, and otherwise sits in BIL, a cash-like short-term Treasury fund.
This strategy watches one stock: Cue Biopharma (CUE), a small biotech company that can move sharply on news.
Each day it checks CUE’s 14-day RSI, a simple score of how heavily the stock has been sold lately. If that score is below 30, the strategy buys CUE, assuming it may be due for a rebound. If not, it moves into BIL, a very short-term U.S. Treasury fund used like cash.
Rule-based strategy shows higher OOS growth: ~16.1% yearly vs SPY 14.9%, with Calmar ~0.32 and Sharpe ~0.52, and beta ~0.60. Diversified by cash when not in CUE; note biotech drawdowns can be larger.
1M
3M
6M
YTD
1Y
3Y
Max
Performance
Compared to selected benchmarks
| Alpha | Beta | R2 | R | |
|---|---|---|---|---|
| 0.21 | 0.14 | 0.01 | 0.08 |
Performance Metrics
| Cumulative Return | Annualized Return | Trailing 1M Return | Trailing 3M Return | Sharpe Ratio | |
|---|---|---|---|---|---|
| 195.47% | 13.15% | -5.4% | -4.54% | 0.74 | |
| 389.97% | 19.87% | 0.33% | 0.93% | 0.68 |
Initial Investment
$10,000.00
Final Value
$48,997.24Regulatory Fees
$49.19
Total Slippage
$369.91
Invest in this strategy
OOS Start Date
Nov 7, 2024
Trading Setting
Daily
Type
Stocks
Category
Rsi, mean reversion, single-stock biotech, tactical allocation, cash equivalent, daily rebalance
Tickers in this symphonyThis symphony trades 2 assets in total
Ticker
Type
BIL
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
Stocks
CUE
Cue Biopharma, Inc.
Stocks